MARKET NEWS

 

Yourway Breaks Ground on Major Expansion, Including Phase 1 Clinical Trials Unit
Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-Targeting TriTAC HPN424
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of its Adenosine A2A Receptor Antagonist
IN8bio Completes Treatment of First Cohort in Phase 1 Clinical Trial With Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme
Cullinan Oncology Announces Phase 1/2a Interim Data for Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

  FEATURED EDITORIAL

  COMPANY PROFILE

Pfanstiehl is a global leader in the manufacture of cGMP high purity, low endotoxin, low metal injectable-grade excipients and biopharmaceutical components for upstream bioprocessing, downstream formulation, and specialty applications. In addition, Pfanstiehl is a leading contract development and manufacturing organization (CDMO) specializing in the isolation, purification, custom synthesis, and scale-up development of small molecule Active Pharmaceutical Ingredients (APIs), in gram to multi-ton commercial quantities. While most ingredient manufacturers or resellers focus on other industries, such as food, cosmetics, agriculture, and/or nutritional supplements, offering only a subset of ‘pharma- grade’ ingredients, Pfanstiehl is Pharma Grade through and through. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Cyclerion Therapeutics Announces Global Licensing Agreement With Akebia Therapeutics

Cyclerion Therapeutics Announces Global Licensing Agreement With Akebia Therapeutics

Cyclerion Therapeutics, Inc. recently announced it has entered into an exclusive, global license agreement with Akebia Therapeutics, Inc., a leading biopharmaceutical company focused on kidney disease, for the….

Noble Further Expands Capabilities of Its New Human Factors + Program

Noble Further Expands Capabilities of Its New Human Factors + Program

In direct response to the rapid growth of the recently launched Human Factors + (HF+) program, Noble, an Aptar Pharma company, recently announced the….

Bayer to Advance Two First-of-its-Kind Cell & Gene Therapies for Parkinson’s Disease

Bayer to Advance Two First-of-its-Kind Cell & Gene Therapies for Parkinson’s Disease

Bayer AG recently announced that BlueRock Therapeutics (BlueRock) successfully administered the first dose of its pluripotent stem cell-derived dopaminergic neurons, named DA01, to a….

Akoya & AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology

Akoya & AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology

Akoya Biosciences, Inc. recently announced a collaboration with AstraZeneca to advance new multiplex immunofluorescence (mIF) workflows and spatial biomarker signatures….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 23 – Controlled Release
June 30 – Drug Delivery